Physicians’ perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey

Several novel compounds are being developed for inflammatory bowel diseases (IBD). In addition, biosimilar drugs are being approved. An increasing number of head‐to‐head, superiority and non‐inferiority trials in patients with IBD are expected in the future. The clinical relevance of the magnitude of the effect size is often debated.

[1]  C. Swanton,et al.  Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP). , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  M. Neurath,et al.  Current and emerging therapeutic targets for IBD , 2017, Nature Reviews Gastroenterology & Hepatology.

[3]  L. Peyrin-Biroulet,et al.  Head-to-head Comparative Studies: Challenges and Opportunities? , 2016, Journal of Crohn's & colitis.

[4]  J. Choe,et al.  A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy , 2015, Annals of the rheumatic diseases.

[5]  W. Sandborn,et al.  Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. , 2017, The New England journal of medicine.

[6]  S. Bonovas,et al.  Biosimilars in IBD: from theory to practice , 2017, Nature Reviews Gastroenterology &Hepatology.

[7]  L. Peyrin-Biroulet,et al.  Next generation of small molecules in inflammatory bowel disease , 2016, Gut.

[8]  W. Sandborn,et al.  Next-Generation Therapeutics for Inflammatory Bowel Disease , 2016, Current Gastroenterology Reports.

[9]  P. Rutgeerts,et al.  Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. , 2016, The New England journal of medicine.

[10]  G. D'Haens,et al.  Next-Generation Therapeutics for IBD , 2015, Current Gastroenterology Reports.

[11]  A. Hart,et al.  Clinical trials in luminal Crohn's disease: a historical perspective. , 2014, Journal of Crohn's & colitis.

[12]  Anna Tostevin,et al.  An observational multi-cohort study on the use and safety of Combivir scored tablets among HIV-infected children and adolescents. Report to the European Medicines Agency (EMA)/ Committee for Medicinal Products for Human Use (CHMP) , 2014 .

[13]  P. Rutgeerts,et al.  Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. , 2014, Gastroenterology.

[14]  P. Rutgeerts,et al.  Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. , 2014, Gastroenterology.

[15]  Kristin Stephens,et al.  Vedolizumab as induction and maintenance therapy for Crohn's disease. , 2013, The New England journal of medicine.

[16]  P. Rutgeerts,et al.  Vedolizumab as induction and maintenance therapy for ulcerative colitis. , 2013, The New England journal of medicine.

[17]  Edgar Ramiterre,et al.  A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study , 2013, Annals of the rheumatic diseases.

[18]  P. Rutgeerts,et al.  Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. , 2012, Gastroenterology.

[19]  G. D'Haens,et al.  Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. , 2012, Gastroenterology.

[20]  S. Schreiber.  Certolizumab pegol for the treatment of Crohn’s disease , 2011, Therapeutic advances in gastroenterology.

[21]  P. Rutgeerts,et al.  Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.

[22]  English Only,et al.  GUIDELINES ON EVALUATION OF SIMILAR BIOTHERAPEUTIC PRODUCTS (SBPs) , 2009 .

[23]  S. Schreiber,et al.  Maintenance therapy with certolizumab pegol for Crohn's disease. , 2007, The New England journal of medicine.

[24]  S. Targan,et al.  Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. , 2007, Gastroenterology.

[25]  P. Rutgeerts,et al.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. , 2007, Gastroenterology.

[26]  Paul Rutgeerts,et al.  Infliximab for induction and maintenance therapy for ulcerative colitis. , 2005, The New England journal of medicine.

[27]  S. Hanauer,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[28]  B. Rowe,et al.  SEROTYPING OF E. COLI , 1976, The Lancet.

[29]  I. Leodolter.  [Crohn's disease]. , 1967, Wiener Zeitschrift fur innere Medizin und ihre Grenzgebiete.

[30]  G PLACITELLI,et al.  [Ulcerative colitis]. , 1958, La Riforma medica.